

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	LaColla <i>et al.</i>	Confirmation No.:	9201
Serial No.:	10/609,298	Art Unit:	1623
Filed:	June 27, 2003	Examiner:	T. McIntosh III
For:	2' AND 3' NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS	Attorney Docket No: (CAM: IDX 1017	11874-016-999 417451-999016)

TERMINAL DISCLAIMER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The owners of the entire interest in the above-identified application, Idenix Pharmaceuticals, Inc., Universita Degli Studi Di Cagliari and Centre National de la Recherche Scientifique (collectively, "owners"), hereby disclaim the terminal part of the statutory term of any patent granted on the above-identified application which would extend beyond the expiration date of the statutory terms of any patent granted on pending U.S. Patent Application No. 10/602,691. The owners hereby waive the right to separately enforce any patent granted on pending U.S. Patent Application No. 10/602,691 and any patent granted on the above-identified application. The owners hereby agree that any patent granted on pending U.S. Patent Application No. 10/602,691 and any patent granted on the above-identified application shall be enforceable only for and during such period that any patent granted on pending U.S. Patent Application No. 10/602,691 and any patent granted on the above-identified application are not separately enforced.

Ownership of the above-identified application in Idenix Pharmaceuticals, Inc., Universita Degli Studi Di Cagliari and Centre National de la Recherche Scientifique is demonstrated by virtue of assignments recorded November 11, 2008 at reel 021819 frame 0136; November 11, 2008 at reel 021819 frame 0145; and November 11, 2008 at reel 021819 frame 0149.

Ownership of U.S. Patent Application No. 10/602,691 in Idenix Pharmaceuticals, Inc. and Universita Degli Studi Di Cagliari is demonstrated by virtue of assignments recorded September 13, 2001 at reel 012162 frame 0294 and August 19, 2002 at reel 013193 frame 0841.

The owners further agree that the waiver, and this agreement, run with any patent granted on the above-identified application and are binding upon the owners, their successors, or assigns.

The owners do not disclaim any terminal part of any patent granted on the above-identified

application prior to the expiration date of the full statutory term of any patent granted on U.S. Patent Application No. 10/602,691 in the event that said patent later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321(a), has all claims canceled by a reexamination certificate, or is otherwise terminated prior to the expiration of the full statutory term, except for the waiver and this agreement as stated above.

The undersigned hereby confirm that they have reviewed the assignments and, to the best of their knowledge and belief, title is in the assignees seeking to take action in this matter and that they are empowered to act on behalf of Idenix Pharmaceuticals, Inc., Universita Degli Studi Di Cagliari and Centre National de la Recherche Scientifique.

The undersigned hereby declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Idenix Pharmaceuticals, Inc.

Date: November 26, 2003 By: [Signature]

Name: MARIA D. STARR

Position: Vice President, Patent & Regulatory Affairs

Universita Degli Studi di Cagliari

Date: _____ By: _____

Name:

Position:

Centre National de la Recherche Scientifique

Date: _____ By: _____

Name:

Position:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	LaColla <i>et al.</i>	Confirmation No.:	9201
Serial No.:	10/609,298	Art Unit:	1623
Filed:	June 27, 2003	Examiner:	T. McIntosh III
For:	2' AND 3' NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS	Attorney Docket No:	11874-016-999
		(CAM:	417451-999016)
			IDX 1017

TERMINAL DISCLAIMER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The owners of the entire interest in the above-identified application, Idenix Pharmaceuticals, Inc., Universita Degli Studi Di Cagliari and Centre National de la Recherche Scientifique (collectively, "owners"), hereby disclaim the terminal part of the statutory term of any patent granted on the above-identified application which would extend beyond the expiration date of the statutory terms of any patent granted on pending U.S. Patent Application No. 10/602,691. The owners hereby waive the right to separately enforce any patent granted on pending U.S. Patent Application No. 10/602,691 and any patent granted on the above-identified application. The owners hereby agree that any patent granted on pending U.S. Patent Application No. 10/602,691 and any patent granted on the above-identified application shall be enforceable only for and during such period that any patent granted on pending U.S. Patent Application No. 10/602,691 and any patent granted on the above-identified application are not separately enforced.

Ownership of the above-identified application in Idenix Pharmaceuticals, Inc., Universita Degli Studi Di Cagliari and Centre National de la Recherche Scientifique is demonstrated by virtue of assignments recorded November 11, 2008 at reel 021819 frame 0136; November 11, 2008 at reel 021819 frame 0145; and November 11, 2008 at reel 021819 frame 0149.

Ownership of U.S. Patent Application No. 10/602,691 in Idenix Pharmaceuticals, Inc. and Universita Degli Studi Di Cagliari is demonstrated by virtue of assignments recorded September 13, 2001 at reel 012162 frame 0294 and August 19, 2002 at reel 013193 frame 0841.

The owners further agree that the waiver, and this agreement, run with any patent granted on the above-identified application and are binding upon the owners, their successors, or assigns.

The owners do not disclaim any terminal part of any patent granted on the above-identified

application prior to the expiration date of the full statutory term of any patent granted on U.S. Patent Application No. 10/602,691 in the event that said patent later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321(a), has all claims canceled by a reexamination certificate, or is otherwise terminated prior to the expiration of the full statutory term, except for the waiver and this agreement as stated above.

The undersigned hereby confirm that they have reviewed the assignments and, to the best of their knowledge and belief, title is in the assignees seeking to take action in this matter and that they are empowered to act on behalf of Idenix Pharmaceuticals, Inc., Universita Degli Studi Di Cagliari and Centre National de la Recherche Scientifique.

The undersigned hereby declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Idenix Pharmaceuticals, Inc.

Date: _____ By: _____

Name: _____

Position: _____

19 DIC. 2008

Certifico l'Ufficiale Rogante Sostituto dell'Università degli Studi di Cagliari che la firma apposta in mia presenza Prof. Adolfo Lai nato a Ottana (SS) 08.07.1953, Pro Rettore dell'Università di Cagliari e della cui identità personale sono certo è autentica.

L'Ufficiale Rogante Sostituto Dr. Adolfo Filiberto Putzu

Università Degli Studi di Cagliari

Name: _____

Position: _____

Centre National de la Recherche Scientifique

Date: _____ By: _____

Name: _____

Position: _____

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	LaColla <i>et al.</i>	Confirmation No.:	9201
Serial No.:	10/609,298	Art Unit:	1623
Filed:	June 27, 2003	Examiner:	T. McIntosh III
For:	2' AND 3' NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS	Attorney Docket No: (CAM:	11874-016-999 417451-999016) IDX 1017

TERMINAL DISCLAIMER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The owners of the entire interest in the above-identified application, Idenix Pharmaceuticals, Inc., Universita Degli Studi Di Cagliari and Centre National de la Recherche Scientifique (collectively, "owners"), hereby disclaim the terminal part of the statutory term of any patent granted on the above-identified application which would extend beyond the expiration date of the statutory terms of any patent granted on pending U.S. Patent Application No. 10/602,691. The owners hereby waive the right to separately enforce any patent granted on pending U.S. Patent Application No. 10/602,691 and any patent granted on the above-identified application. The owners hereby agree that any patent granted on pending U.S. Patent Application No. 10/602,691 and any patent granted on the above-identified application shall be enforceable only for and during such period that any patent granted on pending U.S. Patent Application No. 10/602,691 and any patent granted on the above-identified application are not separately enforced.

Ownership of the above-identified application in Idenix Pharmaceuticals, Inc., Universita Degli Studi Di Cagliari and Centre National de la Recherche Scientifique is demonstrated by virtue of assignments recorded November 11, 2008 at reel 021819 frame 0136; November 11, 2008 at reel 021819 frame 0145; and November 11, 2008 at reel 021819 frame 0149.

Ownership of U.S. Patent Application No. 10/602,691 in Idenix Pharmaceuticals, Inc. and Universita Degli Studi Di Cagliari is demonstrated by virtue of assignments recorded September 13, 2001 at reel 012162 frame 0294 and August 19, 2002 at reel 013193 frame 0841.

The owners further agree that the waiver, and this agreement, run with any patent granted on the above-identified application and are binding upon the owners, their successors, or assigns.

The owners do not disclaim any terminal part of any patent granted on the above-identified

application prior to the expiration date of the full statutory term of any patent granted on U.S. Patent Application No. 10/602,691 in the event that said patent later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321(a), has all claims canceled by a reexamination certificate, or is otherwise terminated prior to the expiration of the full statutory term, except for the waiver and this agreement as stated above.

The undersigned hereby confirm that they have reviewed the assignments and, to the best of their knowledge and belief, title is in the assignees seeking to take action in this matter and that they are empowered to act on behalf of Idenix Pharmaceuticals, Inc., Universita Degli Studi Di Cagliari and Centre National de la Recherche Scientifique.

The undersigned hereby declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Idenix Pharmaceuticals, Inc.

Date: _____ By: _____
Name:
Position:

Universita Degli Studi di Cagliari

Date: _____ By: _____
Name:
Position:

Centre National de la Recherche Scientifique

Date: 04 DEC. 2008 By: _____
Name: Directeur de la Politique Industrielle
Position: Marc J. LEDOUX

